Skip to main content

. 1986 Aug;22(2):199–200. doi: 10.1111/j.1365-2125.1986.tb05251.x

Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.

T Inaba, R E Tyndale, W A Mahon

PMCID: PMC1401106 PMID: 3756068

199

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Eichelbaum M. Polymorphic drug oxidation in humans. Fed Proc. 1984 May 15;43(8):2298–2302. [PubMed] [Google Scholar]
Inaba T., Jurima M., Mahon W. A., Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos. 1985 Jul-Aug;13(4):443–448. [PubMed] [Google Scholar]
Inaba T., Vinks A., Otton S. V., Kalow W. Comparative pharmacogenetics of sparteine and debrisoquine. Clin Pharmacol Ther. 1983 Mar;33(3):394–399. doi: 10.1038/clpt.1983.51. [DOI] [PubMed] [Google Scholar]
Lennard M. S. Oxidation phenotype and the metabolism and action of beta-blockers. Klin Wochenschr. 1985 Apr 1;63(7):285–292. doi: 10.1007/BF01731972. [DOI] [PubMed] [Google Scholar]
Otton S. V., Inaba T., Kalow W. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci. 1984 Jan 2;34(1):73–80. doi: 10.1016/0024-3205(84)90332-1. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES